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excluded. The query identified 142 patients who received 
treatment for clinical Stage II disease. Median age was 38 years 
(range: 19 – 68), 33 had Stage IIA, 47 IIB, and 62 had IIC disease. 
Fifty-nine patients were treated with radiation therapy (RT) 
while 83 received chemotherapy (CT). Only three patients with 
Stage IIA got CT, and only five with IIC got RT. Median RT dose 
was 30 Gy. Most common CT regimens used were EP (n = 68) and 
BEP (n = 13). 
Results: After a median follow up of 18 years, 24 patients had 
died, and there were 16 recurrences (three in the contra-lateral 
testis). Patients were more likely to die of second cancers (n = 
7) and myocardial infarctions (n = 6), than from progressive 
Seminoma (n = 3). Two patients died during treatment 
(neutropenia and sepsis). The 10- and 15-year overall survival 
(OS) was, IIA: 93.8% and 93.8%; IIB: 91.4% and 88.3%; IIC: 83.2% 
and 76.0%. The 10-year cumulative incidence of relapse (CIR) for 
Stage IIA patients treated with RT was 3.4%. Stage IIC patients 
treated with CT had a 10-yr CIR of 10.6%. The 10-year CIR for 
Stage IIB patients treated with RT (n = 24) versus CT (n = 23) was 
29.8% versus 0% (p = 0.005). Seventeen patients developed a 
second malignancy (SM); non-melanoma skin cancers were 
excluded. The 15-year cumulative incidence of SM was 7.3% for 
patients treated with RT, versus 9.7% for those treated with CT 
(p = 0.321). 
Conclusions:  Long-term outcomes for patients with Stage II 
Seminoma continue to be excellent. Patients are more likely to 
die of second cancers and cardiovascular disease than from 
progressive seminoma. 
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Purpose: To describe the practice of adjuvant brachytherapy 
(BT) and external beam radiotherapy (EBRT) for management of 
endometrial cancer.  
Methods and Materials: An electronic survey including 83 
questions focusing on general/demographic information, pre-
treatment assessments, radiotherapy policies and EBRT/BT 
techniques was sent to all 14 regional cancer centres in 2014.  
Results: The response rate was 100%. The most frequently used 
dose/fractionation scheme for EBRT was 45 Gy in 25 fractions. 
The EBRT technique was 4-Field box in 46%, IMRT in 15%, VMAT 
in 31% and VMAT/4-Field box in 8% of the centres. Pelvic EBRT 
was recommended by all centres for Stage II/IIIA/IIIC1 any grade, 
by 92% of the centres with Stage IB Grade 3 or serous-clear cell 
carcinoma/Stage IIIC2 any grade and by 70% of the centres for 
Stage IA serous-clear cell carcinoma. Combination of EBRT and 
BT was recommended by all centres for Stage II any grade 
carcinoma, by 92% of the centres for Stage IIIC1 with cervical 
stromal involvement, by 85% of the centres for Stage 
IIIA/IIIB/IIIC2 with cervical stromal involvement and by 54% of 
the centres for Stage IVB any grade with cervical stromal 
involvement. Adjuvant BT alone was recommended for Stage 1A 
Grade 3 or Stage 1B Grade 1-2 in 77% of the centres, for Stage 
1A serous-clear cell carcinoma in 31% of centres, for Stage 1B 
Grade 3 in 15% of centres. In 85% of centres, the cases were 
always peer reviewed. Half of the centres used image 
verification with x-ray/CT/fluoroscopy after each insertion of 
the applicator. Bladder and rectal doses were recorded in 8% of 
the centres using ICRU 38 point doses and in 25% using dose-
volume metrics (D2cc). Seventeen percent of the centres treated 
the upper 3 cm of the vagina, 42% the upper 4 cm, 8% the upper 
3-4 cm, 8% the upper 5 cm, 17% the upper half and 8% the upper 
third of the vagina. The dose was prescribed at the surface of 
the cylinder and at a depth of 5 mm in 33% and 67% of the 
centres, respectively. The dose for BT alone prescribed to the 
surface varied from 6-10.5 Gy x 3-5 fractions. The dose was more 
uniform when prescribed at depth, with 87% using 7 Gy x 3 
fractions. For combination EBRT-BT treatments, BT dose varied 
from 5-6 Gy x 3 fractions at the surface to 4-5.5 Gy x 2-3 fractions 
at depth.  
Conclusions: Practice patterns regarding the use of EBRT and BT 
appear to be fairly consistent across the province of Ontario, 
however, there is considerable heterogeneity in BT treatment 
planning practices, particularly with respect to length of vagina 
treated, prescription points, and dose/fractionation. Further 
research is required to determine the reasons for this 
heterogeneity, to identify areas where harmonization of practice 
might lead to clinically significant benefits, and to generate 
evidence–based practice recommendations for the use of EBRT 
and BT in the province of Ontario. 
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Purpose: Our region has higher than provincial average smoking 
rates and alcohol consumption and lower human papillomavirus 
(HPV) vaccination rates. These have contributed to high 
incidence and poor prognosis of head and neck squamous cell 
carcinoma (HNSCC) in the past. This study reviews our single 
institution experience with Stage 4A and 4B HNSCC outcomes 
during 4 years since we adopted Intensity Modulated 
Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) 
and Image-guided Radiation Therapy (IGRT). 
Methods and Materials: All charts of patients with head and neck 
malignancy between August 2009 and July 2013 were reviewed. 
Total of 195 consecutive patients met the selection criteria for 
analysis. There were 100 Stage 4A or 4B locally advanced HNSCC 
(AJCC-7). 
Results: Median age was 63 years (36-88), 81% were male, 21% 
were P16 positive (the most biologically relevant indicator for 
HPV-induced oropharyngeal squamous cell carcinoma), 74% had 
two or more major comorbidities. Most common sites are 
oropharynx (52%), hypopharynx (13%) and larynx (10%). Majority 
96% received radiotherapy, including 90% IMRT and 37% VMAT, 
86% received 50 Gy or higher dose, 39% had surgery, and 62% had 
chemotherapy. Using Kaplan-Meier life table, the 2/3 year local 
regional control rates are 82.8% and 80.5% respectively, and the 
2/3 year overall survival rates are 62.3% and 57.4% respectively. 
Median survival has not been reached. There was no treatment 
related death and 25% had Grade 3-4 acute toxicity (RTOG Acute 
Radiation Morbidity Scoring Criteria). 
Conclusions: Stage 4A and 4B HNSCC outcome in our institution 
is better than historical data. This might be due to our 
multidisciplinary approach and the introduction of new 
technology including IMRT, VMAT, and IGRT. Normal tissue 
tolerance dose constraints usually can be met using IMRT or 
VMAT. The local regional control and overall survival is excellent 
despite significant comorbidities associated with unhealthy life 
style in this region. 
 
 
 
 
 
